These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 20003758

  • 1. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.
    Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D, Tharavanij T, Mendez AJ, Ricordi C, Alejandro R.
    Cell Transplant; 2009; 18(10):1247-59. PubMed ID: 20003758
    [Abstract] [Full Text] [Related]

  • 2. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, Cure PE, Monroy K, Mendez A, Selvaggi G, Ricordi C, Alejandro R.
    Transplantation; 2008 Jul 15; 86(1):36-45. PubMed ID: 18622276
    [Abstract] [Full Text] [Related]

  • 3. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
    Sahraoui A, Winzell MS, Gorman T, Smith DM, Skrtic S, Hoeyem M, Abadpour S, Johansson L, Korsgren O, Foss A, Scholz H.
    PLoS One; 2015 Jul 15; 10(3):e0121204. PubMed ID: 25793295
    [Abstract] [Full Text] [Related]

  • 4. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.
    Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, Mineo D, Baidal DA, Cure P, Ponte G, Mendez AJ, Selvaggi G, Ricordi C, Alejandro R.
    Transplantation; 2008 Dec 27; 86(12):1658-65. PubMed ID: 19104401
    [Abstract] [Full Text] [Related]

  • 5. Effect of exenatide on gastric emptying and graft survival in islet allograft recipients.
    Peixoto EM, Froud T, Gomes LS, Zavala LM, Corrales A, Herrada E, Ricordi C, Alejandro R.
    Transplant Proc; 2011 Nov 27; 43(9):3231-4. PubMed ID: 22099764
    [Abstract] [Full Text] [Related]

  • 6. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation.
    Park YJ, Ao Z, Kieffer TJ, Chen H, Safikhan N, Thompson DM, Meloche M, Warnock GL, Marzban L.
    Diabetologia; 2013 Mar 27; 56(3):508-19. PubMed ID: 23262664
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M, Ahrén B.
    Horm Metab Res; 2004 Mar 27; 36(11-12):795-803. PubMed ID: 15655711
    [Abstract] [Full Text] [Related]

  • 8. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S, Astiarraga B, Tura A, Frascerra S, Ciociaro D, Mari A, Gastaldelli A, Ferrannini E.
    Diabetes Obes Metab; 2017 Mar 27; 19(3):412-420. PubMed ID: 27898183
    [Abstract] [Full Text] [Related]

  • 9. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Luo J, Nguyen K, Chen M, Tran T, Hao J, Tian B, Rulifson IC, Zhang Y, Tian L, Zhang Y, Lopez E, Lin DC, Wang Y, Ma Z, Houze J, Guo Z.
    Metabolism; 2013 Jan 27; 62(1):90-9. PubMed ID: 22982177
    [Abstract] [Full Text] [Related]

  • 10. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.
    Transplantation; 2007 Jan 15; 83(1):24-8. PubMed ID: 17220786
    [Abstract] [Full Text] [Related]

  • 11. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V, Zheng D, Stefanovski D, Bergman RN.
    Am J Physiol Endocrinol Metab; 2008 Aug 15; 295(2):E269-77. PubMed ID: 18492781
    [Abstract] [Full Text] [Related]

  • 12. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
    Mooradian AD, Albert SG, Bernbaum M, Plummer S.
    Diabetes Care; 1996 Aug 15; 19(8):883-4. PubMed ID: 8842609
    [Abstract] [Full Text] [Related]

  • 13. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA.
    J Diabetes Sci Technol; 2014 Sep 15; 8(5):1011-7. PubMed ID: 25030181
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M, Troskot R.
    Minerva Endocrinol; 2015 Mar 15; 40(1):71-83. PubMed ID: 25366984
    [Abstract] [Full Text] [Related]

  • 16. Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.
    Aston-Mourney K, Hull RL, Zraika S, Udayasankar J, Subramanian SL, Kahn SE.
    Diabetologia; 2011 Jul 15; 54(7):1756-65. PubMed ID: 21484213
    [Abstract] [Full Text] [Related]

  • 17. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
    Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H.
    Biochem Biophys Res Commun; 2009 Dec 18; 390(3):809-14. PubMed ID: 19836346
    [Abstract] [Full Text] [Related]

  • 18. In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice.
    Suen PM, Li K, Chan JC, Leung PS.
    Int J Biochem Cell Biol; 2006 Dec 18; 38(5-6):951-60. PubMed ID: 16172015
    [Abstract] [Full Text] [Related]

  • 19. Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.
    Crutchlow MF, Yu M, Bae YS, Deng S, Stoffers DA.
    Transplant Proc; 2008 Jun 18; 40(5):1650-7. PubMed ID: 18589167
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of glucagon secretion.
    Young A.
    Adv Pharmacol; 2005 Jun 18; 52():151-71. PubMed ID: 16492545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.